Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Exact Sciences (EXAS) Tops Q1 EPS by 4c
April 26, 2018 4:22 PM EDTExact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.33), $0.04 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $86.93 million.
"The Exact Sciences team delivered strong growth to start the year by remaining relentlessly focused... More
